Soluble RAGEs - Prospects for treating & tracking metabolic and inflammatory disease

Vascular Pharmacology

Volumn 72, Issue , 2015, Pages 1-8

  Schmidt, Ann Marie ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Soluble RAGE

Indexed keywords

ADAM10 ENDOPEPTIDASE; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALOGLIPTIN; AMYLOID BETA PROTEIN; ATORVASTATIN; AZELNIDIPINE; BIOLOGICAL MARKER; CALGRANULIN; CELL SURFACE RECEPTOR; ESTRADIOL; HIGH MOBILITY GROUP B1 PROTEIN; LIGAND; MATRIX METALLOPROTEINASE; METHOTREXATE; MYELOID DIFFERENTIATION FACTOR 88; PHOSPHATIDYLSERINE; PIOGLITAZONE; PITAVASTATIN; SOLUBLE ADVANCED GLYCATION END PRODUCT RECEPTOR; SULFONYLUREA; TELMISARTAN; UNCLASSIFIED DRUG;

CELL SURFACE; CHRONIC DISEASE; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DIABETIC PATIENT; GLYCEMIC CONTROL; HUMAN; INFLAMMATORY DISEASE; INSULIN TREATMENT; METABOLIC DISORDER; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; ANIMAL; BLOOD; INFLAMMATION;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ANIMALS; BIOMARKERS; HUMANS; INFLAMMATION; METABOLIC DISEASES;

EID: 84939569848     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2015.06.011     Document Type: Review

References (68)

1. Daffu G., del Pozo C.H., O'Shea K.M., Ananthakrishnan R., Ramasamy R., Schmidt A.M. Radical roles for RAGE in the pathogenesis of oxidative stress in cardiovascular diseases and beyond. Int. J. Mol. Sci. 2013, 14:19891-19910.
2. Litwinoff E.M., Hurtado Del Pozo C., Ramasamy R., Schmidt A.M. Emerging targets for therapeutic development in diabetes and its complications: the RAGE signaling pathway. Clin. Pharmacol. Ther. 2015, (epub ahead of print). 10.1002/cpt.148.
3. Manigrasso M.B., Juranek J., Ramasamy R., Schmidt A.M. Unlocking the biology of RAGE in diabetic microvascular complications. Trends Endocrinol. Metab. 2014, 25:15-22.
4. Ramasamy R., Yan S.F., Schmidt A.M. The diverse ligand repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes. Vascul. Pharmacol. 2012, 57:160-167.
5. Gaens K.H., Goossens G.H., Niessen P.M., van Greevenbroek M.M., van der Kallen C.J., Niessen H.W., et al. Nepsilon-(carboxymethyl)lysine-receptor for advanced glycation end product axis is a key modulator of obesity-induced dysregulation of adipokine expression and insulin resistance. Arterioscler. Thromb. Vasc. Biol. 2014, 34:1199-1208.
6. Song F., Hurtado del Pozo C., Rosario R., Zou Y.S., Ananthakrishnan R., Xu X., et al. RAGE regulates the metabolic and inflammatory response to high-fat feeding in mice. Diabetes 2014, 63:1948-1965.
7. Reiniger N., Lau K., McCalla D., Eby B., Cheng B., Lu Y., et al. Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse. Diabetes 2010, 59:2043-2054.
8. More S.S., Vartak A.P., Vince R. Restoration of glyoxalase enzyme activity precludes cognitive dysfunction in a mouse model of Alzheimer's disease. ACS Chem. Neurosci. 2013, 4:330-338.
9. Yan S.D., Chen X., Fu J., Chen M., Zhu H., Roher A., et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996, 382:685-691.
10. Zeng S., Zhang Q.Y., Huang J., Vedantham S., Rosario R., Ananthakrishnan R., et al. Opposing roles of RAGE and Myd88 signaling in extensive liver resection. FASEB J. 2012, 26:882-893.
11. Liliensiek B., Weigand M.A., Bierhaus A., Nicklas W., Kasper M., Hofer S., et al. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J. Clin. Invest. 2004, 113:1641-1650.
12. He M., Kubo H., Morimoto K., Fujino N., Suzuki T., Takahasi T., et al. Receptor for advanced glycation end products binds to phosphatidylserine and assists in the clearance of apoptotic cells. EMBO Rep. 2011, 12:358-364.
13. Rai V., Toure F., Chitayat S., Pei R., Song F., Li Q., et al. Lysophosphatidic acid targets vascular and oncogenic pathways via RAGE signaling. J. Exp. Med. 2012, 209:2339-2350.
14. Maillard-Lefebvre H., Boulanger E., Daroux M., Gaxatte C., Hudson B.I., Lambert M. Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases. Rheumatology (Oxford) 2009, 48:1190-1196.
15. Vazzana N., Santilli F., Cuccurullo C., Davi G. Soluble forms of RAGE in internal medicine. Intern. Emerg. Med. 2009, 4:389-401.
16. Yamagishi S., Matsui T., Nakamura K. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes. Curr. Drug Targets 2007, 8:1138-1143.
17. Raucci A., Cugusi S., Antonelli A., Barabino S.M., Monti L., Bierhaus A., et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 2008, 22:3716-3727.
18. Zhang L., Bukulin M., Kojro E., Roth A., Metz V.V., Fahrenholz F., et al. Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J. Biol. Chem. 2008, 283:35507-35516.
19. Yonekura H., Yamamoto Y., Sakurai S., Petrova R.G., Abedin M.J., Li H., et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem. J. 2003, 370:1097-1109.
20. Hiratsuka S., Watanabe A., Sakurai Y., Akashi-Takamura S., Ishibashi S., Miyake K., et al. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat. Cell Biol. 2008, 10:1349-1355.
21. Park J.S., Gamboni-Robertson F., He Q., Svetkauskaite D., Kim J.Y., Strassheim D., et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am. J. Physiol. Cell Physiol. 2006, 290:C917-C924.
22. Santilli F., Blardi P., Scapellato C., Bocchia M., Guazzi G., Terzuoli L., et al. Decreased plasma endogenous soluble RAGE, and enhanced adipokine secretion, oxidative stress and platelet/coagulative activation identify non-alcoholic fatty liver disease among patients with Familial Combined Hyperlipidemia and/or Metabolic syndrome. Vascul. Pharmacol. 2015, 72:16-24.
23. Pertynska-Marczewska M., Merhi Z. Relationship of advanced glycation end products with cardiovascular disease in menopausal women. Reprod. Sci. 2015, 22(7):774-782. PMID: 25228634.
24. Mukhopadhyay S., Mukherjee T.K. Bridging advanced glycation end product, receptor for advanced glycation end product and nitric oxide with hormonal replacement/estrogen therapy in healthy versus diabetic postmenopausal women: a perspective. Biochim. Biophys. Acta 2005, 1745:145-155.
25. Tanaka N., Yonekura H., Yamagishi S., Fujimori H., Yamamoto Y., Yamamoto H. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J. Biol. Chem. 2000, 275:25781-25790.
26. Pullerits R., d'Elia H.F., Tarkowski A., Carlsten H. The decrease of soluble RAGE levels in rheumatoid arthritis patients following hormone replacement therapy is associated with increased bone mineral density and diminished bone/cartilage turnover: a randomized controlled trial. Rheumatology (Oxford) 2009, 48:785-790.
27. Humpert P.M., Papadopoulos G., Schaefer K., Djuric Z., Konrade I., Morcos M., et al. sRAGE and esRAGE are not associated with peripheral or autonomic neuropathy in type 2 diabetes. Horm. Metab. Res. 2007, 39:899-902.
28. Koyama H., Shoji T., Fukumoto S., Shinohara K., Shoji T., Emoto M., et al. Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease. Arterioscler. Thromb. Vasc. Biol. 2007, 27:147-153.
29. Koyama H., Yamamoto H., Nishizawa Y. RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases. Mol. Med. 2007, 13:625-635.
30. Semba R.D., Ferrucci L., Fink J.C., Sun K., Beck J., Dalal M., et al. Advanced glycation end products and their circulating receptors and level of kidney function in older community-dwelling women. Am. J. Kidney Dis. 2009, 53:51-58.
31. Prasad K. Low levels of serum soluble receptors for advanced glycation end products, biomarkers for disease state: myth or reality. Int. J. Angiol. 2014, 23:11-16.
32. Colhoun H.M., Betteridge D.J., Durrington P., Hitman G., Neil A., Livingstone S., et al. Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial. Diabetes 2011, 60:2379-2385.
33. Bobek D., Grcevic D., Kovacic N., Lukic I.K., Jelusic M. The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus. Pediatr. Rheumatol. Online J. 2014, 12:50.
34. Emanuele E., D'Angelo A., Tomaino C., Binetti G., Ghidoni R., Politi P., et al. Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch. Neurol. 2005, 62:1734-1736.
35. Falcone C., Emanuele E., D'Angelo A., Buzzi M.P., Belvito C., Cuccia M., et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1032-1037.
36. Geroldi D., Falcone C., Emanuele E., D'Angelo A., Calcagnino M., Buzzi M.P., et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J. Hypertens. 2005, 23:1725-1729.
37. Ilzecka J. Serum-soluble receptor for advanced glycation end product levels in patients with amyotrophic lateral sclerosis. Acta Neurol. Scand. 2009, 120:119-122.
38. Jiao L., Weinstein S.J., Albanes D., Taylor P.R., Graubard B.I., Virtamo J., et al. Evidence that serum levels of the soluble receptor for advanced glycation end products are inversely associated with pancreatic cancer risk: a prospective study. Cancer Res. 2011, 71:3582-3589.
39. Ma C.Y., Ma J.L., Jiao Y.L., Li J.F., Wang L.C., Yang Q.R., et al. The plasma level of soluble receptor for advanced glycation end products is decreased in patients with systemic lupus erythematosus. Scand. J. Immunol. 2012, 75:614-622.
40. McNair E.D., Wells C.R., Mabood Qureshi A., Basran R., Pearce C., Orvold J., et al. Soluble receptors for advanced glycation end products (sRAGE) as a predictor of restenosis following percutaneous coronary intervention. Clin. Cardiol. 2010, 33:678-685.
41. Miniati M., Monti S., Basta G., Cocci F., Fornai E., Bottai M. Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study. Respir. Res. 2011, 12:37.
42. Yao Y., Zhuang J., Li Y., Jing B., Li H., Li J., et al. Association of polymorphisms of the receptor for advanced glycation end products gene and susceptibility to sporadic abdominal aortic aneurysm. Biomed. Res. Int. 2015, 2015:394126.
43. Glasnovic A., Cvija H., Stojic M., Tudoric-Deno I., Ivcevic S., Romic D., et al. Decreased level of sRAGE in the cerebrospinal fluid of multiple sclerosis patients at clinical onset. Neuroimmunomodulation 2014, 21:226-233.
44. Narvaez-Rivera R.M., Rendon A., Salinas-Carmona M.C., Rosas-Taraco A.G. Soluble RAGE as a severity marker in community acquired pneumonia associated sepsis. BMC Infect. Dis. 2012, 12:15.
45. Piarulli F., Sartore G., Lapolla A. Glyco-oxidation and cardiovascular complications in type 2 diabetes: a clinical update. Acta Diabetol. 2013, 50:101-110.
46. Lertwittayapon T., Tencomnao T., Santiyanont R. Inhibitory effect of alternatively spliced RAGEv1 on the expression of NF-kB and TNF-alpha in hepatocellular carcinoma cells. Genet. Mol. Res. 2012, 11:1712-1720.
47. Shemirani F., Yazdanparast R. The interplay between hyperglycemia-induced oxidative stress markers and the level of soluble receptor for advanced glycation end products (sRAGE) in K562 cells. Mol. Cell. Endocrinol. 2014, 393:179-186.
48. Quade-Lyssy P., Kanarek A.M., Baiersdorfer M., Postina R., Kojro E. Statins stimulate the production of a soluble form of the receptor for advanced glycation end products. J. Lipid Res. 2013, 54:3052-3061.
49. Lam J.K., Wang Y., Shiu S.W., Wong Y., Betteridge D.J., Tan K.C. Effect of insulin on the soluble receptor for advanced glycation end products (RAGE). Diabet. Med. 2013, 30:702-709.
50. Nakamura K., Yamagishi S., Nakamura Y., Takenaka K., Matsui T., Jinnouchi Y., et al. Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvasc. Res. 2005, 70:137-141.
51. Koyama H., Tanaka S., Monden M., Shoji T., Morioka T., Fukumoto S., et al. Comparison of effects of pioglitazone and glimepiride on plasma soluble RAGE and RAGE expression in peripheral mononuclear cells in type 2 diabetes: randomized controlled trial (PioRAGE). Atherosclerosis 2014, 234:329-334.
52. Tahara N., Yamagishi S., Mizoguchi M., Tahara A., Imaizumi T. Pioglitazone decreases asymmetric dimethylarginine levels in patients with impaired glucose tolerance or type 2 diabetes. Rejuvenation Res. 2013, 16:344-351.
53. Tan K.C., Chow W.S., Tso A.W., Xu A., Tse H.F., Hoo R.L., et al. Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes. Diabetologia 2007, 50:1819-1825.
54. Yanagisawa K., Ashihara J., Obara S., Wada N., Takeuchi M., Nishino Y., et al. Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargine-injected diabetic patients. Diabetes Metab. Res. Rev. 2014, 30:693-700.
55. Arabi Y.M., Dehbi M., Rishu A.H., Baturcam E., Kahoul S.H., Brits R.J., et al. sRAGE in diabetic and non-diabetic critically ill patients: effects of intensive insulin therapy. Crit. Care 2011, 15:R203.
56. Sakata K., Hayakawa M., Yano Y., Tamaki N., Yokota N., Eto T., et al. Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes. Diabetes Metab. Res. Rev. 2013, 29:624-630.
57. Forbes J.M., Soderlund J., Yap F.Y., Knip M., Andrikopoulos S., Ilonen J., et al. Receptor for advanced glycation end-products (RAGE) provides a link between genetic susceptibility and environmental factors in type 1 diabetes. Diabetologia 2011, 54:1032-1042.
58. Nakamura T., Sato E., Fujiwara N., Kawagoe Y., Koide H., Ueda Y., et al. Calcium channel blocker inhibition of AGE and RAGE axis limits renal injury in nondiabetic patients with stage I or II chronic kidney disease. Clin. Cardiol. 2011, 34:372-377.
59. Forbes J.M., Thorpe S.R., Thallas-Bonke V., Pete J., Thomas M.C., Deemer E.R., et al. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J. Am. Soc. Nephrol. 2005, 16:2363-2372.
60. Fukushima Y., Daida H., Morimoto T., Kasai T., Miyauchi K., Yamagishi S., et al. Relationship between advanced glycation end products and plaque progression in patients with acute coronary syndrome: the JAPAN-ACS sub-study. Cardiovasc. Diabetol. 2013, 12:5.
61. Tam H.L., Shiu S.W., Wong Y., Chow W.S., Betteridge D.J., Tan K.C. Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes. Atherosclerosis 2010, 209:173-177.
62. Santilli F., Bucciarelli L., Noto D., Cefalu A.B., Davi V., Ferrante E., et al. Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic. Biol. Med. 2007, 43:1255-1262.
63. Huang S.M., Chang Y.H., Chao Y.C., Lin J.A., Wu C.H., Lai C.Y., et al. EGCG-rich green tea extract stimulates sRAGE secretion to inhibit S100A12-RAGE axis through ADAM10-mediated ectodomain shedding of extracellular RAGE in type 2 diabetes. Mol. Nutr. Food Res. 2013, 57:2264-2268.
64. Soop A., Sunden-Cullberg J., Albert J., Hallstrom L., Treutiger C.J., Sollevi A. Adenosine infusion attenuates soluble RAGE in endotoxin-induced inflammation in human volunteers. Acta Physiol. (Oxf.) 2009, 197:47-53.
65. Pullerits R., Bokarewa M., Dahlberg L., Tarkowski A. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res. Ther. 2005, 7:R817-R824.
66. Sung J.Y., Chung W., Kim A.J., Kim H.S., Ro H., Chang J.H., et al. Calcitriol treatment increases serum levels of the soluble receptor of advanced glycation end products in hemodialysis patients with secondary hyperparathyroidism. Tohoku J. Exp. Med. 2013, 230:59-66.
67. Brix J.M., Hollerl F., Kopp H.P., Schernthaner G.H., Schernthaner G. The soluble form of the receptor of advanced glycation endproducts increases after bariatric surgery in morbid obesity. Int. J. Obes. (Lond.) 2012, 36:1412-1417.
68. Parikh M., Chung M., Sheth S., McMacken M., Zahra T., Saunders J.K., et al. Randomized pilot trial of bariatric surgery versus intensive medical weight management on diabetes remission in type 2 diabetic patients who do NOT meet NIH criteria for surgery and the role of soluble RAGE as a novel biomarker of success. Ann. Surg. 2014, 260:617-622. (discussion 22-4).